Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review

Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review

Schizophrenia is a complex psychiatric disorder often resistant to dopamine-targeting antipsychotics. Cobenfy, a combination of xanomeline and trospium chloride, offers a novel approach by modulating muscarinic receptors while minimizing side effects. This review evaluates its efficacy and safety,...

Full description

Saved in:
Bibliographic Details
Main Authors: Michał Mazur, Katarzyna Żak, Katarzyna Michalak, Krystian Zukierski, Weronika Jarych, Aleksandra Pliszka, Hubert Jucha, Katarzyna Madyniak, Agnieszka Kluz
Format: Article
Language:English
Published: Nicolaus Copernicus University in Toruń 2025-04-01
Series:Quality in Sport
Subjects:
Cobenfy
xanomeline-trospium
muscarinic receptor modulation
schizophrenia treatment
non-dopaminergic antipsychotics
EMERGENT trials
Online Access:https://apcz.umk.pl/QS/article/view/59815
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://apcz.umk.pl/QS/article/view/59815

Similar Items